Perpetual LTD Gilead Sciences, Inc. Transaction History

Perpetual LTD

$9.23 Trillion
Q3 2024

A detailed history of Perpetual LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Perpetual LTD holds 16,154 shares of GILD stock, worth $1.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

16,154

Previous 16,154 -0.0%

Holding current value

$1.45 Million

Previous $1.11 Billion 22.2%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$63.15 - $72.88 $142,719 - $164,708	2,260 Added 16.27%	16,154 $1.11 Billion
Q1 2024 Apr 09, 2024	BUY	$71.58 - $87.29 $787 - $960	11 Added 0.08%	13,894 $1.02 Billion
Q4 2023 Feb 15, 2024	SELL	$73.27 - $83.09 $2.2 Million - $2.49 Million	-30,026 Reduced 68.38%	13,883 $1.12 Billion
Q3 2023 Oct 10, 2023	SELL	$73.94 - $80.67 $290,953 - $317,436	-3,935 Reduced 8.22%	43,909 $3.29 Billion
Q2 2023 Jul 13, 2023	SELL	$76.01 - $86.7 $422,235 - $481,618	-5,555 Reduced 10.4%	47,844 $3.69 Billion
Q1 2023 May 08, 2023	BUY	$77.31 - $88.08 $2.94 Million - $3.35 Million	38,062 Added 248.17%	53,399 $4.43 Billion
Q3 2020 Dec 08, 2020	BUY	$62.1 - $78.08 $58,187 - $73,160	937 Added 6.51%	15,337 $969,000
Q2 2020 Nov 18, 2020	BUY	$72.34 - $84.0 $1.04 Million - $1.21 Million	14,400 New	14,400 $2.34 Million
Q1 2020 Nov 18, 2020	SELL	$62.63 - $80.22 $901,872 - $1.16 Million	-14,400 Closed	0 $0
Q2 2019 Jul 30, 2019	SELL	$61.87 - $69.38 $129,927 - $145,698	-2,100 Reduced 12.73%	14,400 $973,000
Q2 2018 Jul 23, 2018	BUY	$64.88 - $75.68 $1.07 Million - $1.25 Million	16,500 New	16,500 $1.17 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perpetual LTD, based on Form 13F filings with the SEC.

News

Stay updated on Perpetual LTD with notifications on news.

Account